Coloplast ASCLPBF 72 Return-on-Tangible-Asset is -20.42% as of Mar. 2026. GuruFocus rates CLPBF with a GF Score™ of 72/100 and a GF Value™ of $129.03 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Coloplast AS ranks better than 86.53% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Coloplast AS's annualizedNet Income for the quarter that ended in Mar. 2026 was $-601 Mil. Coloplast AS's average total tangible assets for the quarter that ended in Mar. 2026 was $2,942 Mil. Therefore, Coloplast AS's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -20.42%.
The historical rank and industry rank for Coloplast AS's Return-on-Tangible-Asset or its related term are showing as below:
CLPBF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 11.41 Med: 37.13 Max: 41.37
Current: 11.41
During the past 13 years, Coloplast AS's highest Return-on-Tangible-Asset was 41.37%. The lowest was 11.41%. And the median was 37.13%.
CLPBF's Return-on-Tangible-Asset is ranked better than 86.53% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.595
vs CLPBF: 11.41
Coloplast AS (OTCPK:CLPBF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Coloplast AS Return-on-Tangible-Asset Related Terms
Coloplast AS Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLPBF vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Coloplast AS's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Coloplast AS's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -20.42% mean?
Coloplast AS (CLPBF) has a Return-on-Tangible-Asset of -20.42% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Coloplast AS and its competitors. Over the past decade, Coloplast AS's Return-on-Tangible-Asset has ranged from 11.41 to 41.37. According to the industry distribution chart, Coloplast AS ranks #115 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 13.5%.
Is Coloplast AS's Return-on-Tangible-Asset too high?
Coloplast AS's current Return-on-Tangible-Asset is -20.42%. Over the past 10 years, this metric has ranged from a low of 11.41 to a high of 41.37. Based on the distribution chart, Coloplast AS ranks #115 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Coloplast AS has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #115 out of 854 companies for Return-on-Tangible-Asset. This places Coloplast AS in the top 14% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.60. Historically, Coloplast AS's own Return-on-Tangible-Asset has ranged from 11.41 to 41.37 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.60, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Coloplast AS and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current Return-on-Tangible-Asset is -20.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $129.03, compared to a current price of $61.76 — trading 52.1% below its estimated fair value. The current Return-on-Tangible-Asset is -20.42%. Coloplast AS's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Coloplast AS (CLPBF), the current Return-on-Tangible-Asset is -20.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBF) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $61.76 is trading 52.1% below its estimated GF Value™ of $129.03.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBF:
Return-on-Tangible-Asset: -20.42%
GF Value™: $129.03 vs. price of $61.76 (52.1% below fair value)
No single metric tells the full story. See the CLPBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
72GF Score
Get the complete analysis for CLPBF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBF has been successfully added to your 
